Chemical Structure (Talzenna 01)
Talzenna Capsule, Liquid Filled
Product Images NDC 63539-031
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Talzenna (NDC 63539-031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Talzenna 02)
This data represents the progression-free survival of patients treated with Talzenna versus chemotherapy over a period of 39 months. The number of patients at risk in each group is provided for each time point, showing a higher number of patients on Talzenna at the beginning of the study with a gradual decrease over time. This information is valuable for understanding the effectiveness of Talzenna compared to traditional chemotherapy in terms of progression-free survival.*
Figure 2 (Talzenna 03)
This is a graph showing the Overall Survival Probability (%) for two different treatments - TALZENNA and Chemotherapy. The x-axis represents time in months, while the y-axis shows the survival probability percentage. The number of patients at risk is also indicated at different time points for each treatment.*
Figure 3 (Talzenna 03a)
This is not-readable.*
Logo (Talzenna 04)
This text is not available.*
Logo (Talzenna 04a)
This text provides information about a company named Pfizer Labs, which is a division of Pfizer Inc. based in New York. It also includes the address of the company as New York, NY 10001. Pfizer Labs is known for its distribution of products.*
Principal Display Panel (0.5 mg Capsule Bottle Label)
The text provides information on how to store the medication Talzenna (talazoparib) capsules, the recommended dosage, and the pharmaceutical company distributing them. It also mentions that it is a professional sample and not for sale. The capsules contain 0.5 mg of talazoparib. The text includes the product name, NDC number, and GTIN code.*
Principal Display Panel (1 mg Capsule Bottle Label)
This text provides information on the storage conditions of Talzenna capsules, the recommended dosage, and details about the product. It mentions the temperature range for storage, the dosage amount of talazoparib present in each capsule, the distributor (U.S. Pharmaceuticals Pfizer Inc.), and that the product is made in Germany. Additionally, it is specified that this is a professional sample and not for sale, with the National Drug Code (NDC) and barcode information included.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
